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ABSTRACT
Objective: The main objective of the study was to formulate and evaluate the chitosan nanoparticles to improve the therapeutic efficacy of itraconazole 
by loading in nanoparticle drug delivery system. Designing the formulation of the drug itraconazole prolongs the therapeutic concentration of the 
drug in the blood and which will lower the frequency of dosing and also improves the efficacy of the drug.
Methods: Itraconazole nanoparticles are prepared by ionic gelation method; here, chitosan is used as polymer. The formulated nanoparticles are 
evaluated for external morphological studies by scanning electron microscope (SEM), drug content, in vitro drug release studies, as well as infrared 
(IR) spectral analysis.
Results: The Fourier transform IR spectra show that there was no interaction between drug and polymers; hence, they are compatible. Percentage 
entrapment efficiency, drug content, and percentage yield were higher for F3 formulation. The particle size analysis shows that every particle in the 
formulations gave the range of 148–227 nm, respectively; increasing in the particle size observed with varying concentration of polymer. SEM analysis 
of the nanoparticles shows that all the formulations were spherical and smooth with ideal surface morphology. As the concentration of polymer, the 
drug release decreased proportionally. The stability studies were carried out on the optimized formulation for 2 months at 30±2°C and 60±5% RH and 
40±2°C and 75±5% RH; finally, it was observed that there was no change in drug content and in vitro drug release profile even after storage at 30±2°C 
and 60±5% RH and 40±2°C and 75±5% RH for 2 months.
Conclusion: Itraconazole is one among the most widely used antifungal drugs. Designing the formulation of drug itraconazole prolongs therapeutic 
drug concentration in the blood and decreases dosage frequency and also enhances the efficacy of drug.
Keywords: Itraconazole, Nanoparticles, Ionic gelation method, Chitosan.
INTRODUCTION
The current years have witnessed the extraordinary growth of research 
and application in the area of nanoscience. There is increased confidence 
that nanotechnology is applied to medicine. It will convey important 
advances in the diagnosis and treatment of various diseases [1].
Nanotechnology carrier for targeted drug delivery systems
The nano-based carrier molecules are more advantageous because it 
acted for both site specific and organ specific. Reaching the nano or 
micron range of particles makes them to be highly potential carriers 
in lots of biological molecules. The carrier’s surface properties can be 
improved for targeted drug delivery [2].
Targeted nano-based drug carriers enhance half-life of the drug molecules, 
decrease drug toxicity, and provide effective drug distribution. Drug 
carriers guarantee to deliver drugs to many anatomic extremity of the 
body such as blood–brain barrier and tight epithelial junctions of the skin. 
Drug carriers effectively penetrate tumors due to their leaky constitution, 
containing pores which range from diameter 100 to 1000 nm.
Antifungal agents
Antifungal agents are mainly defined as substance that kills or 
inhibits their growth or reproduction of fungi. An antifungal such 
as amphotericin B and ketoconazole, both effective against a broad 
spectrum of fungi, most probably these antifungals act by binding the 
sterols which are present in the fungal plasma membrane and alter its 
membrane permeability [3]. An invasive fungal infection is becoming 
an increased cause of human mortality and morbidity, particularly 
for immune compromised populations [2,4]. The fungal pathogens 
Cryptococcus neoformans, Candida albicans, and Aspergillus fumigatus 
collectively contribute to 1 million human deaths annually.
EXPERIMENTAL METHODS
Materials
Itraconazole was obtained from Sigma-Aldrich, Chennai, India. Chitosan 
was gotten from Sigma-Aldrich, Chennai, India. Every other chemical 
utilized was of the standard analytical review.
Identification tests
Solubility analysis
The spontaneous interaction of two or more substance to form a 
homogenous molecular dispersion is called as solubility [5]. 10 mg of 
drug was dissolved in 10 ml of different solvents at room temperature.
Determination of melting point
The melting points of drugs were determined by means of capillary 
technique. Observed value was compared with the reported standard 
value.
Formulation of itraconazole nanoparticles
Preparation of chitosan gel
Chitosan gel solution (0.2% W/V) was prepared by dispersing 200 mg 
of chitosan in 100 ml of glacial acetic acid solution (1% V/V) with 
continuous stirring of 2 h. Further, the prepared solution was kept 
overnight for the formation of clear gel.
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Ionic gelation method
Itraconazole with constant concentration was added to different 
concentrations of the polymer prepared from the above chitosan gel to 
achieve 1:1, 1:2, 1:3, and 1:4 ratio. A different concentration (0.1 and 
0.2 % w/v) of sodium tripolyphosphate solution was prepared and 
added dropwise to chitosan solution with continuous stirring for 1 h 
by sonication. The obtained suspension was centrifuged at 10,000 rpm 
for 10 min. The pellets obtained were resuspended in deionized water 
by sonication, then centrifuged and dried at room temperature [6,7]. 
The different formulations of itraconazole nanoparticles are shown in 
Table 1.
Characterization and evaluation of nanoparticles
Production yield (%)
The production yield of nanoparticles from different batches was 
calculated by the weight of dried final product with the drug and 
polymers initial total weight which is used for the preparation of 
nanoparticles [8].
% PY = WO/WT × 100
Where, PY = Production yield; WO = Practical mass (nanoparticles); and 
WT = Theoretical mass (polymer + drug).
Particle size analysis
The particle sizes of nanoparticles, that are not visible in the optical 
microscope, were measured by scanning electron microscopy (SEM) 
using Malvern Particle Size Analyzer (Mastersizer 2000). Samples were 
prepared by dispersing the nanoparticles using required quantity of 
water to attain 5% obscuration. Particle size distribution data are used 
to determine the average particle size [9,10].
Differential scanning calorimetry (DSC)
DSC of itraconazole, chitosan, and nanoparticles of itraconazole 
chitosan was done using Shimadzu DSC-60 Calorimeter, Tokyo, Japan.
Surface morphology
Surface morphology and shape of nanoparticles are observed with 
the aid of SEM (JEOL-JSM-AS430, Japan). The prepared and dried 
nanoparticles mounted to a metal stub and were coated by conductive 
gold as sputter coater joined to the instrument [11,12].
Drug entrapment and drug content
Initially, the prepared nanoparticles were dissolved in distilled water and 
ultracentrifuged at 10,000 rpm for 30 min for determining encapsulation 
efficiency [13,14]. The liquid phases consist of free itraconazole that 
is measured by UV spectrophotometry at 269 nm. The itraconazole 
entrapment efficacy is calculated by the below-mentioned formula.
Entrapment efficiency (%) = (Tp–Tf) 100/Tp
Where, Tp is the total itraconazole used to prepare the nanoparticles 
and Tf is the free itraconazole in the supernatant.
Drug content was calculated as follows:
DC (%) = A-B/C ×100
Where, DC = Drug loading; A = Weight of drug loaded in nanoparticles; 
C = Total weight of nanoparticles; and B = Free Itraconazole.
In vitro release studies
Accurately weighed nanoparticle samples were added to a dialysis 
membrane and kept in the dissolution medium at 37±2°C with 50 rpm. 
1 ml of dissolution media was withdrawn every 1 h and supplanted 
by utilizing parallel amount of the liquid and keep up constant 
volume [15]. The withdrawn samples were analyzed at 269 nm using 
spectrophotometer.
Stability studies
Stability studies were employed as per the ICH guidelines at 30°C/60% 
RH and 40°C/75% RH for the selected formulations for 60 days and 
evaluated for their drug content and in vitro dissolution profile [16,17].
RESULTS AND DISCUSSION
Solubility analysis
Itraconazole showed good solubility in chloroform and DMSO; however, 
it displays insolubility in water. Solubility analysis is necessary because 
the drug must be dissolved in the solvents and the dissolution medium 
used.
Melting point determination
The melting point of the drug was observed at 166°C. The obtained 
result consistent with the reported range (164–168°C) and conforms 
to known standards, thereby shows purity of the drug used in the study.
Compatibility studies
IR study
FT-IR spectroscopy study was used to check the compatibility between 
the drug itraconazole and the polymer chitosan used for the preparation 
of itraconazole nanoparticles. The obtained IR spectrum of the pure 
itraconazole was compared with functional group frequencies of 
standard. The results proved that there were no significant interactions 
between the drug and chitosan. The results are shown in Figs. 1-3.
DSC
Thermal behavior of itraconazole in nanoparticles was studied using 
DSC to observe the effect of polymer on itraconazole. The results are 
shown in Figs. 4-6.
Characterization and evaluation of nanoparticles
Production yield (%)
The percentage yields of nanoparticles were observed in the range 
of 89–95.12%. It was found that production yield of nanoparticles 
prepared by 1:3 concentrations showed greater production yield than 
the other prepared concentrations. The results are shown in Table 2.
Entrapment efficiency and drug content
The entrapment efficiency and drug content of different formulations 
are shown in Table 3. It was observed that the formulation F3 gave the 
highest entrapment efficiency and drug content.
Particle size analysis and zeta potential
Particle size and zeta potential of all the formulations are shown 
in Table 4. The particle size analysis was carried out using optical 
microscopy and zeta potential will be measured using Malvern 
instrument. It shows that all formulations provided particles in the 
range of 148–227 nm, respectively. Increasing in the particle size 
observed with varying concentration of polymer in increasing order.
Table 1: Formulation of itraconazole nanoparticles
Formulations code Concentration of drug (mg) Conc. of polymer (mg) Drug‑polymer ratio Conc. of TPP (%)
ICNP-1 100 100 01:01 0.10
ICNP-2 100 200 01:02 0.10
ICNP-3 100 300 01:03 0.20
ICNP-4 100 400 01:04 0.20
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Surface morphology
SEM of the formulation F3 is shown in Fig. 7(a and b) which showed 
that the nanoparticles were discrete, spherical, and uniform with a 
smooth surface.
In vitro release
The in vitro release of itraconazole from prepared formulation of 
nanoparticles was studied using phosphate buffer at pH 7.4 for 8 h. 
The in vitro release data are shown in Table 5, and the graphical 
representation is shown in Fig. 8.
Stability studies
Stability studies of the prepared itraconazole nanoparticles were 
carried out by storing the optimized formulation F3 at 30±2°C and 
60±5% RH and 40±2°C and 75±5% RH for 60 days. Two parameters, 
namely in vitro release studies and percentage drug content, were 
carried out. The results are presented in Tables 6 and 7. It was observed 
that there was no change in drug content and in vitro drug release 
profile even after storage at 30±2°C and 60±5% RH and 40±2°C and 
75±5% RH for 60 days.
Fig. 1: Fourier transform infrared spectrum of pure itraconazole
Fig. 2: Fourier transform infrared spectrum of chitosan
Fig. 3: Fourier transform infrared spectrum of itraconazole + chitosan
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Fig. 4: Differential scanning calorimetry of itraconazole
Fig. 5: Differential scanning calorimetry of chitosan
Table 2: Production yield of different formulations





Table 3: Drug content and entrapment efficiency of different 
formulations





Table 4: Particle size analysis of different formulations






Itraconazole is one of the most widely used antifungal drugs. 
Itraconazole nanoparticles are prepared by ionic gelation technique. 
Designing a sustained release formulation for the drug Itraconazole may 
prolong therapeutic concentration of drug in the blood and decrease 
frequency of dosing and also improve the therapeutic efficacy of drug. 
Hence, an attempt was made to formulate the nanoparticles antifungal 
drug. This study confirms that the ionic gelation technique is apt for 
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Fig. 6: Differential scanning calorimetry of a mixture of itraconazole and chitosan
Fig. 7: (a) External morphological studies scanning electron 
microscope (SEM), (b) External Morphological Studies (SEM)
Table 5: Comparative in vitro drug release of different 
formulations
S. No Time (h) % drug release
ICNP1 ICNP2 ICNP3 ICNP4
1 0 0 0 0 0
2 1 8.64 8.15 7.32 6.64
3 2 17.25 15.38 16.38 14.32
4 3 27.13 26.43 25.05 24.11
5 4 39.06 38.06 37.62 34.84
6 5 56.52 54.43 57.06 51.92
7 6 67.25 64.79 63.96 65.29
8 7 82.85 78.29 75.09 73.55
9 8 91.03 89.51 85.92 83.21
Table 6: In vitro drug release studies after storing at different 
temperatures (F3)
S. No Time (h) Percentage (%) drug release
0 day 30 days 60 days
30°±2°C 40°±2°C 30°±2°C 40°±2°C
1 0 0 0 0 0 0
2 1 6.64 6.54 6.51 6.54 5.96
3 2 14.32 14.2 14.15 13.8 13.7
4 3 24.11 24.05 23.9 23.75 23.58
5 4 34.84 34.73 34.65 34.22 33.8
6 5 51.92 51.85 51.72 51.58 51.45
7 6 65.29 65.21 65.05 64.96 64.8
8 7 73.55 73.5 73.38 73.3 73.24
9 8 83.21 83.15 83.08 82.95 82.9
Table 7: Drug content after storing at different 
temperatures (F3)




0 day 30 days 60 days 30 days 60 days
1 78.44±0.2 78.38±0.12 78.35±0.08 78.26±0.01 78.20±0.06
ba
Fig. 8: Comparative in vitro drug release of different 
formulations
the preparation of itraconazole nanoparticles with more encapsulation 
efficacy. This formulation can be used to enhance the therapeutic 
efficiency of poorly water-soluble drugs. Thus, this study concluded 
that the itraconazole nanoparticles are suitable candidates that provide 
the best antifungal prolong action of the drug nanoparticles.
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